Want to see JP:4591 full AI Analyst Report?
Top Page
Ribomic, Inc.
(4591)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥85.00
▲(13.33% Upside)
Action:Reiterated
Date:07/09/26
The score is primarily held back by weak financial performance—deep ongoing losses and continued cash burn—despite the benefit of a debt-free balance sheet. Technicals are supportive in the near term (positive MACD; price above key short-term averages), but overbought readings raise pullback risk. Valuation is constrained by unprofitability (negative P/E) and no provided dividend yield.
Positive Factors
Debt-free, net-cash balance sheet
Zero debt and a net-cash position reduce insolvency and refinancing pressure, giving Ribomic more flexibility to fund research while preserving optionality through a difficult development period. The meaningful equity base also provides a stronger cushion than leveraged biotech peers.
Negative Factors
Persistent deep losses
Persistent operating and net losses show that the current business remains far from self-sustaining, despite the latest revenue rebound. Extremely negative margins indicate that sales are still too small relative to expenses, making profitability dependent on substantial future improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free, net-cash balance sheet
Zero debt and a net-cash position reduce insolvency and refinancing pressure, giving Ribomic more flexibility to fund research while preserving optionality through a difficult development period. The meaningful equity base also provides a stronger cushion than leveraged biotech peers.
Read all positive factors
Ribomic, Inc. (4591) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.81B
Dividend YieldN/A
Average Volume (3M)819.14K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth1135.58%
EPS Growth2.37%
CountryJP
Employees25
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-22.85
Shares Outstanding56,572,640
10 Day Avg. Volume1,240,690
30 Day Avg. Volume819,143
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ribomic, Inc. Business Overview & Revenue Model
Company Description
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related mac...
Ribomic, Inc. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.50M | 3.00M | 2.11M | 0.00 | 65.97M | 80.91M |
| Gross Profit | 3.85M | -995.00K | 1.19M | -10.50M | 0.00 | 0.00 |
| EBITDA | -1.23B | -1.20B | -1.05B | -1.11B | -1.79B | -1.73B |
| Net Income | -1.19B | -1.15B | -1.02B | -1.02B | -1.65B | -1.68B |
Balance Sheet | ||||||
| Total Assets | 2.89B | 2.98B | 3.19B | 3.55B | 4.58B | 4.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.78B | 2.83B | 3.04B | 3.40B | 4.33B | 4.70B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 150.03M | 135.09M | 142.21M | 155.81M | 199.30M | 260.53M |
| Stockholders Equity | 2.74B | 2.84B | 3.04B | 3.39B | 4.38B | 4.69B |
Cash Flow | ||||||
| Free Cash Flow | -255.11M | -1.12B | -1.03B | -955.48M | -1.73B | -1.51B |
| Operating Cash Flow | -250.76M | -1.11B | -996.97M | -932.76M | -1.71B | -1.50B |
| Investing Cash Flow | -54.35M | 289.83M | 67.18M | 177.27M | 276.35M | 689.56M |
| Financing Cash Flow | 347.70M | 911.05M | 667.26M | 27.65M | 1.33B | 354.72M |
Ribomic, Inc. Technical Analysis
Positive
75.00
Price Trends
76.66
Positive
74.72
Positive
80.08
Positive
Market Momentum
3.30
Positive
54.43
Neutral
23.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Positive. The current price of 75 is below the 20-day moving average (MA) of 83.55, below the 50-day MA of 76.66, and below the 200-day MA of 80.08, indicating a bullish trend. The MACD of 3.30 indicates Positive momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 23.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4591.
Ribomic, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ¥4.63B | -1.22 | ― | 3.92% | -21.55% | -497.97% | |
50 Neutral | ¥15.18B | -11.55 | ― | ― | ― | -8.52% | |
49 Neutral | ¥4.81B | -3.68 | ― | ― | 1135.58% | 2.37% | |
48 Neutral | ¥141.32B | -38.88 | -7.17% | ― | 0.62% | 27.66% | |
44 Neutral | ¥9.34B | -7.43 | -33.61% | ― | 74.24% | -7.78% |
* General Sector Average
JP:4591
Ribomic, Inc.
84.00
-22.00
-20.75%
JP:4587
Peptidream
1,096.00
-623.50
-36.26%
JP:4571
NanoCarrier Co., Ltd.
100.00
-66.00
-39.76%
JP:2183
Linical Co., Ltd.
204.00
-127.75
-38.51%
JP:4575
CanBas Co., Ltd.
767.00
-360.00
-31.94%
Ribomic, Inc. Corporate Events
Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan
Aug 24, 2026
Ribomic has completed the establishment of all planned clinical trial sites for its Phase 3 study of umedaptanib pegol in paediatric achondroplasia patients in Japan, securing Institutional Review Board approval at six additional locations to reac...
Ribomic Posts Quarterly Loss but Maintains Strong Equity Base and Full-Year Outlook
Aug 13, 2026
Ribomic reported non-consolidated results for the quarter ended June 30, 2026, posting modest operating revenue of ¥4 million and a net loss of ¥270 million, slightly narrower in per-share terms than the prior-year period. Total assets d...
RIBOMIC Begins Phase 3 Trial of Orphan Drug Umedaptanib Pegol for Paediatric Achondroplasia
Jul 2, 2026
RIBOMIC, Inc., a Tokyo-listed clinical-stage pharmaceutical company focused on aptamer-based nucleic acid therapeutics, is advancing treatments for rare and intractable conditions. Its lead candidate, umedaptanib pegol (RBM-007), targets fibroblas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.